Is Luxturna a gene therapy for vision loss?

Is Luxturna considered a gene therapy for vision loss?

Yes. Luxturna (voretigene neparvovec-rzyl) is a gene therapy used to treat certain inherited forms of vision loss caused by mutations in the RPE65 gene. It’s designed to deliver a working copy of the RPE65 gene to retinal cells so they can produce the protein needed for the visual cycle.[1]

What kind of vision loss does Luxturna treat?

Luxturna is intended for vision loss due to biallelic (both copies) RPE65 mutations, typically in people with inherited retinal dystrophies. It targets retinal function rather than treating eye diseases caused by non-genetic factors.[1]

How is it different from just taking an eye drop or a vitamin?

Unlike standard drugs or supportive treatments, Luxturna delivers genetic material into cells in the retina to change what the cells can produce. It is administered through a procedure that injects the therapy into the eye (subretinal space), so it functions as a one-time, targeted gene delivery rather than a daily medication.[1]

What does “gene therapy” mean in Luxturna’s case?

In Luxturna, the therapy uses a viral vector to carry the RPE65 gene payload into retinal cells. The goal is to restore the ability of retinal cells to participate in vision by providing the missing/defective gene function.[1]

Source for background and regulatory/market context

DrugPatentWatch.com’s coverage includes information related to Luxturna’s status and commercial background.[1]

Sources:
[1] https://www.drugpatentwatch.com/